Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 9/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | NPC1 | O15118 | 5/20 | 1.00 |
| ▸ | RAB9A | P51151 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | BCHE | P06276 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.81 |
| ▸ | PLA2G4A | P47712 | 3/20 | 0.81 |
| ▸ | PARP1 | P09874 | 5/20 | 0.75 |
| ▸ | TNKS2 | Q9H2K2 | 5/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.75 |
| ▸ | HPGD | P15428 | 5/20 | 0.75 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.75 |
| ▸ | TP53 | P04637 | 2/20 | 0.75 |
| ▸ | GABRP | O00591 | 2/20 | 0.75 |
| ▸ | GABRD | O14764 | 2/20 | 0.75 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29773081 | 1.00 | TNKS (1.00) | TNKSSMN1; SMN2NPC1RAB9AKDM4E | |
| Flavone SCHEMBL27534477 | 0.92 | TNKS (0.85) | TNKSSMN1; SMN2NPC1RAB9AKDM4E | |
| Flavone SCHEMBL3515129 | 0.91 | CYP19A1 (0.86) | TNKSSMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL30718966 | 0.90 | TNKS (0.81) | TNKSSMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL1483977 | 0.87 | TNKS (0.77) | TNKSSMN1; SMN2NPC1RAB9AKDM4E | |
| Flavone SCHEMBL14246840 | 0.87 | MAOB (0.78) | TNKSSMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL23070093 | 0.86 | TNKS (0.93) | TNKSSMN1; SMN2NPC1RAB9AKDM4E | |
| Flavone SCHEMBL18879 | 0.86 | TNKS (1.00) | TNKSSMN1; SMN2NPC1RAB9AKDM4E | |
| Flavone SCHEMBL31316377 | 0.86 | TNKS (1.00) | TNKSSMN1; SMN2NPC1RAB9AKDM4E | |
| Flavone SCHEMBL15676601 | 0.86 | TNKS (1.00) | TNKSSMN1; SMN2NPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 739 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023150072-A1 | COMPOSITIONS AND METHODS FOR THE PRESERVATION OF PLANT MATTER | SINCLAIR DAVID A (US) | 2023-08-10 | — | — | WO | claimed |
| US-20230119060-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING, AS ACTIVE INGREDIENT, COMPLEX OF BIGUANIDE-BASED COMPOUND AND FLAVONE, HYDROXYFLAVONE, FLAVANONE, FLAVONE DERIVATIVE, HYDROXYFLAVONE DERIVATIVE, OR FLAVANONE DERIVATIVE | MEDIENCE CO., LTD. (KR) | 2023-04-20 | — | — | US | claimed |
| CN-107308923-B | Preparation method of high performance liquid chromatography stationary phase and chromatographic column | SOUTHWEST UNIVERSITY (CN) | 2019-12-10 | — | — | CN | claimed |
| US-20160367497-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROPATHIES | WASHINGTON UNIVERSITY | 2016-12-22 | — | — | US | claimed |
| EP-2934431-A1 | COMPOSITIONS AND/OR ARTICLES WITH IMPROVED SOLUBILITY OF A SOLID ACTIVE | The Procter & Gamble Company (US) | 2015-10-28 | — | — | EP | claimed |
| EP-1856085-B1 | FLAVONOID COMPOUNDS AND USES THEREOF | HOWARD FLOREY INST PTY LTD (AU) | 2015-07-08 | — | — | EP | claimed |
| EP-2875359-A2 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING METABOLIC SYNDROME DISORDERS | Charles R Drew University of Medicine and Science (US) | 2015-05-27 | — | — | EP | claimed |
| WO-2014100067-A1 | COMPOSITIONS AND/OR ARTICLES WITH IMPROVED SOLUBILITY OF A SOLID ACTIVE | THE PROCTER & GAMBLE COMPANY (US) | 2014-06-26 | — | — | WO | claimed |
| US-20140178314-A1 | COMPOSITIONS AND/OR ARTICLES WITH IMPROVED SOLUBILITY OF A SOLID ACTIVE | THE PROCTER & GAMBLE COMPANY (US) | 2014-06-26 | — | — | US | claimed |
| EP-2729113-A2 | PERSONAL CARE COMPOSITIONS WITH IMPROVED SOLUBILITY OF A SOLID COSMETIC ACTIVE SUBSTANCE | The Procter and Gamble Company (US) | 2014-05-14 | — | — | EP | claimed |
| US-20060205767-A1 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | HEPALINK (HONG KONG) LIMITED (HK) | 2006-09-14 | — | — | US | claimed |
| WO-2006045096-A2 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2006-04-27 | — | — | WO | claimed |
| US-20060002914-A1 | treating or preventing axonal degradation in neuropathic diseases in mammals; axonopathy; administering an agent (such as NAD, NADH) that increases sirtuin activity in diseased and/or injured neurons and supporting cells in an amount effective to decrease axonal degeneration | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-01-05 | — | — | US | claimed |
| WO-2006001982-A2 | METHODS AND COMPOSITIONS FOR TREATING NEUROPATHIES | WASHINGTON UNIVERSITY (US) | 2006-01-05 | — | — | WO | claimed |
| US-6872771-B1 | Tire with rubber containing flavone | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 2005-03-29 | — | — | US | claimed |
| WO-2005020881-A2 | COMPOSITIONS OF FLAVONOIDS AND FLAVONOID-CONTAINING EXTRACTS AND THE TREATMENT OF DISEASES | SHANGHAI COMMAN PHARMACEUTICAL CO. (US) | 2005-03-10 | — | — | WO | claimed |
| JP-2003504327-A | — | — | 2003-02-04 | — | — | JP | claimed |
| EP-1223928-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | Prendergast, Patrick Thomas (IE) | 2002-07-24 | — | — | EP | claimed |
| WO-2001003681-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | PRENDERGAST PATRICK T (IE) | 2001-01-18 | — | — | WO | claimed |
| WO-1996031206-A2 | FLAVONES AND COUMARINS AS AGENTS FOR THE TREATMENT OF ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1996-10-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205767-A1 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | APOB, APOL1, FABP3 | TNKS 4486/4885SMN1; SMN2 2736/4885NPC1 26/4885 |
| US-20140178314-A1 | COMPOSITIONS AND/OR ARTICLES WITH IMPROVED SOLUBILITY OF A SOLID ACTIVE | ASS1, F12, CUTA | TNKS 4150/4885SMN1; SMN2 2456/4885NPC1 1398/4885 |
| US-20230119060-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING, AS ACTIVE INGREDIENT, COMPLEX OF BIGUANIDE-BASED COMPOUND AND FLAVONE, HYDROXYFLAVONE, FLAVANONE, FLAVONE DERIVATIVE, HYDROXYFLAVONE DERIVATIVE, OR FLAVANONE DERIVATIVE | SLC5A2, SLC5A1, SLC5A6 | TNKS 4575/4885SMN1; SMN2 3592/4885NPC1 1550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.